Belal Chaudhary

Mr. Belal Chaudhary

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2016 in Vaccines
Verified
Journal Article
Open access
PDF file
BCBelal Chaudhary
Belal Chaudhary
Eyad ElkordEyad Elkord
Eyad Elkord
Recent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.

22 November 2013 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
BCBelal Chaudhary
Belal Chaudhary
YKYazan S Khaled
Yazan S Khaled
BABasil J. Ammori
Basil J. Ammori
Eyad ElkordEyad Elkord
Eyad Elkord

30 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
Eyad ElkordEyad Elkord
Eyad Elkord
MSMay Abd Al Samid
May Abd Al Samid
BCBelal Chaudhary
Belal Chaudhary
Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP Helios, and not FoxP3, is the marker of activated tregs expressing GARP/LAP

11 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMay Abd Al Samid
May Abd Al Samid
BCBelal Chaudhary
Belal Chaudhary
YKYazan S Khaled
Yazan S Khaled
BABasil J. Ammori
Basil J. Ammori
Eyad ElkordEyad Elkord
Eyad Elkord
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients

29 October 2014 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
BCBelal Chaudhary
Belal Chaudhary
Eyad ElkordEyad Elkord
Eyad Elkord
Neuropilin 1 (NRP1) is a transmembrane protein with diverse roles in physiological and pathological settings. NRP1 expression has been reported on T cells in inflammatory microenvironments and in secondary lymphoid tissue. Tumor-infiltrating lymphocytes (TILs) play an important role in cancer prognosis. In this study, we investigated NRP1 expression on TILs and peripheral blood mononuclear cells (PBMCs) from colorectal cancer liver metastases (LI/CRC). TILs from LI/CRC and PBMCs from healthy donors and patients were analyzed for expression of NRP1, in addition to other Treg-related markers. PBMCs were co-cultured in vitro with tumor tissue and analyzed for NRP1 expression. We report for the first time that NRP1 is highly expressed on CD3(+)CD4(+) TILs compared to PBMCs. NRP1 expression correlated closely with CD25 expression in TILs. NRP1 was expressed on both Helios(+) and Helios(-) FoxP3-expressing Tregs and on a FoxP3(-)Helios(-) T cell subset. It was also induced on PBMCs following in vitro co-culture with tumor tissue. NRP1 is upregulated on TILs and can be induced on PBMCs by tumor tissue. Further studies are warranted to define the function of NRP1 on human TILs. As a therapeutic target, NRP1 may allow selective targeting of TIL subsets including suppressive Tregs.

24 March 2014 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
BCBelal Chaudhary
Belal Chaudhary
MSMay Abd Al Samid
May Abd Al Samid
BABasel K Al-Ramadi
Basel K Al-Ramadi
Eyad ElkordEyad Elkord
Eyad Elkord
Regulatory T cells (Tregs) have been characterised in different cancers. They accumulate in peripheral blood and tumour microenvironments where they suppress tumour-specific immune responses, enabling tumours to develop without challenge. This tumour immune evasion represents a major obstacle to successful cancer therapies. Whilst Tregs are generally divided into thymic-derived and peripherally induced, Tregs exhibit a wide spectrum of phenotypes and functional capacity dependent on microenvironment. This phenotypic diversity is also reflected in tumour-infiltrating Treg (TI Treg) populations, which may explain the variable impact of Treg accumulation on prognosis in different cancers. Identifying TI Treg subsets is critical to understand TI Treg biology and for developing effective immunotherapies. This review discusses current and potential markers, and the modulation of these markers in cancer. In addition, we systematically review the clinical impact of Tregs in cancer and their potential as a therapeutic target, with a focus on TI Tregs. TI Tregs represent dynamic and diverse subsets that are key in promoting tumour progression through their suppressive activities. Targeting specific TI Treg subpopulations and functional TI Treg markers represents a feasible therapeutic strategy that might allow reestablishment of antitumour immune responses without affecting physiological immune regulation.